Author

J. J. Gartner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Garcia-Garijo· 1 shared A. Gros· 1 shared A. Schlosser· 1 shared A. Vidal· 1 shared A. Yuste-Estevanez· 1 shared B. R. Webber· 1 shared B. S. Moriarity· 1 shared C. M. Kariya· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Garcia-Garijo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Immunogenicity of non-canonical HLA-tumor ligands identified through proteogenomics

M. Lozano-Rabella, A. Garcia-Garijo, J. Palomero, A. Yuste-Estevanez, F. Erhard, J. Martin-Liberal, M. Ochoa de Olza, I. Matos, J. J. Gartner, M. Ghosh, F. Canals, A. Vidal, J. M. Piulats, X. Matias-Guiu, I. Brana, , A. Gros

The paper investigates the immunogenicity of non-canonical HLA-I ligands from tumor cells and finds they are not recognized by autologous T-cells but can be targeted by donor T-cells, suggesting potential as immunotherapy targets.

bioRxiv · Nov 7, 2022Cancer Biology

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade

D. C. Palmer, B. R. Webber, Y. Patel, M. J. Johnson, C. M. Kariya, W. S. Lahr, M. R. Parkhurst, J. J. Gartner, T. D. Prickett, F. J. Lowery, R. J. Kishton, D. Gurusamy, Z. Franco, S. K. Vodnala, M. D. Diers, , N. P. Restifo

This study shows that CISH knockout in TIL enhances neoantigen reactivity and synergizes with PD1 blockade to improve tumor regression.

bioRxiv · Sep 24, 2020Immunology